IP Library Granted Patent US 9,801,887
Granted Patent B2
US 9,801,887 · App. 13/951,642 · Granted Oct 31, 2017

Method of treatment of aggression

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,801,887
App. No.
13/951,642
Granted
Oct 31, 2017
Kind
B2
Abstract

The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined D2 and D5 antagonistic activity.

Claims (10)

1. A method of treating impulsive aggression in an attention deficit hyperactivity disorder (ADHD) patient, comprising:

(a) selecting a patient with ADHD as the sole condition and manifesting impulsive aggression not controlled by ADHD treatment; and

(b) administering 10 mg/day to 200 mg/day of molindone to the ADHD patient,

wherein the administration decreases instances of impulsivity.

2. The method of claim 1 , wherein the molindone is administered at a dose that is 50% or less of a dose indicated for the use of molindone as an antipsychotic agent.

3. The method of claim 1 , wherein the molindone is administered in a dose range of from 15 mg/day to 120 mg/day.

4. The method of claim 2 , wherein the administration decreases the side effects associated with molindone.

5. The method of claim 4 , wherein the side effects are selected from drowsiness, depression, hyperactivity, euphoria, extrapyramidal reactions, akathisia, akinesia, dystonic syndrome, tardive dyskinesia, tachycardia, nausea, dry mouth, urinary retention, and constipation.

6. The method of claim 2 , wherein the administration results in reduction of undesirable behavior and intolerable side effects.

7. The method of claim 1 , wherein the patient is a child.

Assignments (1)
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2017
From: U.S. BANK NATIONAL ASSOCIATION
To: SUPERNUS PHARMACEUTICALS, INC.
Reel/Frame 044552/0694 →